Harland Sather
Affiliations: | University of Southern California, Los Angeles, CA, United States |
Area:
Public Health, Biostatistics BiologyGoogle:
"Harland Sather"Cross-listing: PHTree
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Steinherz PG, Seibel NL, Sather H, et al. (2019) Treatment of higher risk acute lymphoblastic leukemia in young people (CCG-1961), long-term follow-up: a report from the Children's Oncology Group. Leukemia |
| Hastings C, Gaynon PS, Nachman JB, et al. (2015) Increased post-induction intensification improves outcome in children and adolescents with a markedly elevated white blood cell count (≥200 × 10(9) /l) with T cell acute lymphoblastic leukaemia but not B cell disease: a report from the Children's Oncology Group. British Journal of Haematology. 168: 533-46 |
| Matloub Y, Bostrom BC, Hunger SP, et al. (2011) Escalating intravenous methotrexate improves event-free survival in children with standard-risk acute lymphoblastic leukemia: a report from the Children's Oncology Group. Blood. 118: 243-51 |
| Dreyer ZE, Dinndorf PA, Camitta B, et al. (2011) Analysis of the role of hematopoietic stem-cell transplantation in infants with acute lymphoblastic leukemia in first remission and MLL gene rearrangements: a report from the Children's Oncology Group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 29: 214-22 |
| Stork LC, Matloub Y, Broxson E, et al. (2010) Oral 6-mercaptopurine versus oral 6-thioguanine and veno-occlusive disease in children with standard-risk acute lymphoblastic leukemia: report of the Children's Oncology Group CCG-1952 clinical trial. Blood. 115: 2740-8 |
| Gaynon PS, Angiolillo AL, Carroll WL, et al. (2010) Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A children's oncology group report Leukemia. 24: 285-297 |
| Matloub Y, Bostrom BC, Hunger S, et al. (2010) Children with Down Syndrome (DS) and NCI Standard Risk (SR) Acute Lymphoblastic Leukemia (ALL) Have a Superior Five-Year Event-Free Survival (EFS) When Treated with Escalating Intravenous Methotrexate on the Children's Cancer Group (CCG) Study 1991 Blood. 116: 497-497 |
| Nachman JB, La MK, Hunger SP, et al. (2009) Young adults with acute lymphoblastic leukemia have an excellent outcome with chemotherapy alone and benefit from intensive postinduction treatment: a report from the children's oncology group. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5189-94 |
| Schultz KR, Bowman WP, Aledo A, et al. (2009) Improved early event-free survival with imatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia: a children's oncology group study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 5175-81 |
| Matloub Y, Bostrom BC, Angiolillo AL, et al. (2009) Children with NCI Standard Risk Acute Lymphoblastic Leukemia (ALL) and TEL-AML1 or Favorable Chromosome Trisomies Are Almost Certain to Be Cured with Graduated Intensity Therapy: Results of the CCG - 1991 Study. Blood. 114: 320-320 |